Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.24.00038 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von AnnaLynn M Williams und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY. Hauptthemen laut MEDLINE: Quality of Life, Hodgkin Disease, Brentuximab Vedotin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE There have been no previous longitudinal assessments of health-related quality of life (HRQoL) during treatment for pediatric Hodgkin lymphoma (HL). The addition of brentuximab vedotin (BV) to a multidrug chemotherapy backbone demonstrated superior efficacy to standard chemotherapy for patients with pediatric high-risk HL in the AHOD 1331 trial. However, the impact on HRQoL is unknown. PATIENTS AND METHODS After treatment random assignment, 268 participants older than 11 years were enrolled in a prespecified, longitudinal, patient-reported outcomes substudy. HRQoL was assessed using the seven-item Child Health Ratings Inventories (CHRIs)–Global scale before treatment (T1) and at cycle 2 (T2), cycle 5 (T3), and end of treatment (T4). A clinically meaningful increase in HRQoL was considered 7 points on the CHRIs-Global. Multivariable linear regression estimated associations between demographic/clinical variables and HRQoL at T1. Linear mixed models estimated changes in HRQoL across the treatment arm. RESULTS Participant characteristics were balanced by treatment arm. Ninety-three percent of participants completed the CHRIs at T1, 92% at T2, 89% at T3, and 77% at T4. At T1, female sex and fever ( P < .05) were each associated with worse HRQoL. By T2, participants in the BV arm experienced a statistically and clinically significant improvement in HRQoL (β = 7.3 [95% CI, 3.2 to 11.4]; P ≤ .001), which was greater than the change in the standard arm (difference in change β = 5.1 [95% CI, −0.2 to 10.3]; P = .057). The standard arm did not experience a statistically or clinically significant increase in HRQoL until T4 (β = 9.3 [95% CI, 4.7 to 11.5]; P < .001). CONCLUSION These data demonstrate successful collection of serial HRQoL from youth with high-risk pediatric HL and improvement in HRQoL over the course of initial therapy, sooner and to a greater extent in the group receiving the novel agent BV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY.
- Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
- Department of Biostatistics, University of Florida, Gainesville, FL.
- Department of Pediatrics, University of Chicago Pritzker School of Medicine, Comer Children's Hospital, Chicago, IL.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
- Division of Hematology-Oncology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.
ORCID-Profile: AnnaLynn M Williams, Angie Mae Rodday, Tara O Henderson, Frank G Keller, Kara M Kelly, Susan K Parsons
Förderung
- NCI NIH HHS
Zitieren
APA
Williams, A. M., Rodday, A. M., Pei, Q., Henderson, T. O., Keller, F. G., Punnett, A., Kelly, K. M., Castellino, S. M., & Parsons, S. K. (2024). Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00038
Vancouver
Williams AM, Rodday AM, Pei Q, Henderson TO, Keller FG, Punnett A, et al. Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00038
BibTeX
@article{Williams2024,
author = {Williams, AnnaLynn M and Rodday, Angie Mae and Pei, Qinglin and Henderson, Tara O and Keller, Frank G and Punnett, Angela and Kelly, Kara M and Castellino, Sharon M and Parsons, Susan K},
title = {Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.24.00038}
}
EUVIMED